In silico approaches to explore toxicity end points: issues and concerns for estimating human health effects

The European Chemicals Bureau and the Organisation for Economic Cooperation and Development are currently compiling a sanctioned list of quantitative structure–activity relationship (QSAR) risk assessment models and data sets to predict the physiological properties, environmental fate, ecological effects and human health effects of new and existing chemicals in commerce in the European Union. This action implements the technical requirements of the European Commission’s Registration, Evaluation and Authorisation of Chemicals legislation. The goal is to identify a battery of QSARs that can furnish rapid, reliable and cost-effective decision support information for regulatory decisions that can substitute for results from animal studies. This report discusses issues and concerns that need to be addressed when selecting QSARs to predict human health effect end points.

[1]  Scott D. Kahn,et al.  Current Status of Methods for Defining the Applicability Domain of (Quantitative) Structure-Activity Relationships , 2005, Alternatives to laboratory animals : ATLA.

[2]  J. Contrera,et al.  A new highly specific method for predicting the carcinogenic potential of pharmaceuticals in rodents using enhanced MCASE QSAR-ES software. , 1998, Regulatory toxicology and pharmacology : RTP.

[3]  G. Klopman.  MULTICASE 1. A Hierarchical Computer Automated Structure Evaluation Program , 1992 .

[4]  Munn Sharon j.,et al.  Alternative Approaches Can Reduce the Use of Test Animals under REACH. , 2004 .

[5]  Joseph F Contrera,et al.  QSAR modeling of carcinogenic risk using discriminant analysis and topological molecular descriptors. , 2005, Current drug discovery technologies.

[6]  N. Kruhlak,et al.  An analysis of genetic toxicity, reproductive and developmental toxicity, and carcinogenicity data: I. Identification of carcinogens using surrogate endpoints. , 2006, Regulatory toxicology and pharmacology : RTP.

[7]  L. Hall,et al.  Molecular Structure Description: The Electrotopological State , 1999 .

[8]  R D Benz,et al.  Use of toxicological information in drug design. , 2000, Journal of molecular graphics & modelling.

[9]  N. Kruhlak,et al.  Assessment of the health effects of chemicals in humans: I. QSAR estimation of the maximum recommended therapeutic dose (MRTD) and no effect level (NOEL) of organic chemicals based on clinical trial data. , 2004, Current drug discovery technologies.

[10]  Version,et al.  q)sar Application Toolbox , 2008 .

[11]  Naomi L Kruhlak,et al.  Progress in QSAR toxicity screening of pharmaceutical impurities and other FDA regulated products. , 2007, Advanced drug delivery reviews.

[12]  Naomi L Kruhlak,et al.  Assessment of the health effects of chemicals in humans: II. Construction of an adverse effects database for QSAR modeling. , 2004, Current drug discovery technologies.

[13]  J V Nabholz,et al.  U.S. EPA regulatory perspectives on the use of QSAR for new and existing chemical evaluations. , 1995, SAR and QSAR in environmental research.

[14]  Naomi L Kruhlak,et al.  A comprehensive model for reproductive and developmental toxicity hazard identification: I. Development of a weight of evidence QSAR database. , 2007, Regulatory toxicology and pharmacology : RTP.

[15]  Worth Andrew,et al.  The Development and Validation of Expert Systems for Predicting Toxicity. , 1998 .

[16]  J. Contrera,et al.  Predicting the carcinogenic potential of pharmaceuticals in rodents using molecular structural similarity and E-state indices. , 2003, Regulatory toxicology and pharmacology : RTP.

[17]  J. Contrera,et al.  Carcinogenicity testing and the evaluation of regulatory requirements for pharmaceuticals. , 1997, Regulatory toxicology and pharmacology : RTP.

[18]  N. Kruhlak,et al.  Estimating the safe starting dose in phase I clinical trials and no observed effect level based on QSAR modeling of the human maximum recommended daily dose. , 2004, Regulatory toxicology and pharmacology : RTP.

[19]  Romualdo Benigni,et al.  The Development and Validation of Expert Systems for Predicting Toxicity The Report and Recommendations of an ECVAM / ECB Workshop ( ECVAM Workshop 24 ) , 2002 .

[20]  Naomi L Kruhlak,et al.  A comprehensive model for reproductive and developmental toxicity hazard identification: II. Construction of QSAR models to predict activities of untested chemicals. , 2007, Regulatory toxicology and pharmacology : RTP.

[21]  N. Kruhlak,et al.  In silico screening of chemicals for bacterial mutagenicity using electrotopological E-state indices and MDL QSAR software. , 2005, Regulatory toxicology and pharmacology : RTP.

[22]  J K Haseman,et al.  Use of dual control groups to estimate false positive rates in laboratory animal carcinogenicity studies. , 1986, Fundamental and applied toxicology : official journal of the Society of Toxicology.

[23]  Lutz Müller,et al.  Evaluation of the ability of a battery of three in vitro genotoxicity tests to discriminate rodent carcinogens and non-carcinogens I. Sensitivity, specificity and relative predictivity. , 2005, Mutation research.